Collaboration to produce new clinical stage TB drug candidates
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
List view / Grid view
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
Chemspec Europe 2019 gathers impressive array of industry experts under one roof
A new drug for Huntington disease is found to be safe and lowers levels of the abnormal protein that causes the debilitating disease in patients.
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
Leading international partner to the biopharmaceutical industry Sartorius Stedim Biotech (SSB) has today announced that the new SIMCA® 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics.
The US Food and Drug Administration (FDA) has approved new treatments for heart disease caused by ATTR-CM in adults.
A filter has been designed to create more exact measurements early in the drug development stage and help move a drug to clinical trials faster.
A new study has found that prices for brand-name prescription drugs averaged 3.2 to 4.1 times higher in the US compared with other countries.
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
Marketing authorisation has been recommended in the EU by an EMA committee for Sixmo (buprenorphine) as a substitution treatment for opioid dependence.
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
In a ruling handed down by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent.
According to Rutgers researchers, physicians are scaling back on prescribing antibiotics for long-term acne treatment in favour of a combination of therapies.